MedTrace Logo

Single Arm on the Tolerability of Weekly Nab-paclitaxel

NCT01702844 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-10-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)

Conditions

  • Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Nab-Paclitaxel

Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Jared Weiss, MD · UNC Lineberger Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-25
Primary Completion
2017-06-23
Completion
2019-07-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01702844 on ClinicalTrials.gov